Eden Research Plc · LSE:EDEN
Eden Research — H1 2025 Earnings Presentation
19 slides from Eden Research's earnings presentation, Sep 17, 2025
Slide 1: Eden Research Plc 2025 Interim Results Presentation
EDEN RESEARCH PLC 2025 Interim Results Presentation September 2025
Slide 2: Executive team
Executive team 2 Sean Smith Alex Abrey Chief Executive Officer Chief Financial Officer Over 25 years experience in the Experienced Financial Director to a speciality chemicals and industrial diverse range of businesses including biotechnology industries financial and management consultancy ‐ 11+ yea
Slide 3: Company information
Company information 3 Key statistics Eden is the only UK quoted (AIM: EDEN) company focused on plant-derived biopesticides for sustainable agriculture Regulatory Crop uses Intellectual property and Multiple regulatory expertise in plant-derived clearances (EU, US, AUS, NZ) approvals sustainable chem
Slide 4: Core business, IP & unique selling proposition
Core business, IP & 4 unique selling proposition $11bn 36 Eden’s focus is on developing plant-derived The global biopesticides Number of pesticides biopesticides using its two proprietary technology market is projected to banned in the EU since be worth more than April 2020 platforms: $11 billion by
Slide 5: H1 2025 Commercial and operational highlights
H1, 2025 Commercial and operational highlights 5 • Approval of flagship fungicide product, Mevalone®, for the control of powdery mildew on grapes in California, the largest US market, by far. • Appointment of Andermatt Kenya as the Company's exclusive distribution partner for Mevalone in Kenya. Sale
Slide 6: Financials
Financials 6 • The cash reduction reflects both the sales weighting and the fact that several payments from major customers fell into H2. Forecast H1 H1 to 31 2024 • The Company does not currently expect to need to raise 2025 2024 March 26 additional funds for its existing working capital requiremen
Slide 7: Upcoming newsflow
Upcoming newsflow 7 • Major label extensions for Mevalone in various countries (e.g. France) Q4, 2025/Q1, 2026 • Full approval of Ecovelex in Europe 2026 • Commercial /development agreement(s) for insecticide Q4, 2025/Q1, 2026 • Emergency Use applications for Cedroz (wireworm)* and Ecovelex** H2, 20
Slide 8: Product development roadmap
Product development roadmap 8 Late Product Target Crops/markets Discovery Early development development Partnerships Mevalone (fungicide) Botrytis, powdery High-value fruits & mildew, downy vegetables (EU, US, mildew Oceania) Cedroz (nematicide) Nematodes High-value fruits & vegetables (EU) Ecovelex
Slide 9: Revenue potential by product
Revenue potential by product 9 Total Total • Illustration based upon current and in- EU US process labels, but ignoring future (EU/US) (global) expansions of indicated uses €m €m €m €m • Peak sales generally occur 3 years from Mevalone (botrytis) 3 3 6 15 the launch of a product Mevalone (downy mild
Slide 10: Key partners
Key partners 10 Corteva Agriscience is a publicly traded agricultural company that produces seeds, crop protection products, and digital services. The company was formed in 2019 when DuPont Crop Protection, DuPont Pioneer, and Dow AgroSciences merged and in 2023 had revenue of $17bn. Established in
Slide 11: Market Adoption and Regulatory Overview
Market Adoption 11 and Regulatory Overview Why do farmers use Eden’s products? ‐ Mevalone, Cedroz and Ecovelex are all proven products which… ‐ are reliable complements to conventional control ‐ provide phased release for prolonged effects ‐ are easy to use and apply ‐ provide improved efficacy, sta
Slide 12: Institutional and Directors' Shareholdings
Institutional and Directors’ Shareholdings 12 % of the issued ordinary Share purchases Shareholder Number of shares share capital 2025 Gresham House Asset Management Limited 52,882,786 9.92% Octopus Investments 41,551,047 7.79% Sipcam Oxon S.p.A. 39,285,138 7.37% Canaccord Genuity Wealth Management
Slide 13: Case Study 1: Ecovelex Bird repellent seed treatment
Case Study 1: Ecovelex Ecovelex 13 Bird repellent seed treatment Background Current status Ecovelex is a biological bird Semi-field studies showed repellent seed treatment good efficacy initially for use on maize. Two incumbent ingredients Field trials, undertaken by both parties, showed efficacy an
Slide 14: Case Study 2: Insecticide INO20E Mites, Whiteflies, Aphids, Thrips
Case Study 2: Insecticide INO20E Insecticide 1 14 Mites, Whiteflies, Aphids, Thrips Background Based on Eden’s terpene chemistry as its primary Active Ingredient New formulation technology: TerpenLINK does not require adjuvants or synergists to increase efficacy or persistence Emulsifiable concentra
Slide 15: Case Study 2: Insecticide INO20E Mites, Whiteflies, Aphids, Thrips
Case Study 2: Insecticide INO20E Insecticide 1 15 Mites, Whiteflies, Aphids, Thrips Eden Research | September 2025
Slide 16: Case Study 3: Fungicide Late Blight on Potato, etc.
Case Study 3: Fungicide 2 16 Late Blight on Potato, etc. Background Potato late blight, caused by Phytophthora infestans, remains the most EXP1Y (0.33L/Ha) devastating potato disease in Europe, costing up to €1 billion annually in losses and control measures. Untreated Current management heavily rel
Slide 17: Case Study 3: Fungicide Late Blight on Potato, etc.
Case Study 3: Fungicide 2 17 Late Blight on Potato, etc. Eden Research | September 2025
Slide 18: Investment summary
Investment summary 18 01 Commercialisation Eden is well-placed to further commercialise multiple products in 05 Increase number of commercial partners Opportunity to increase the number order to accelerate growth of commercial partners and diversify product range 02 Technology exploitation Ability t
Slide 19: Thank you
Thank you 19 CONTACT: INFO@EDENRESEARCH.COM LSE: EDEN.L Eden Research | September 2025